Previous Article | Next Article ![]()
Journal of Virology, February 2006, p. 1497-1512, Vol. 80, No. 3
0022-538X/06/$08.00+0 doi:10.1128/JVI.80.3.1497-1512.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Integrated Program in Cellular, Molecular and Biophysical Studies,1 Departments of Microbiology,2 Pediatrics,3 Pathology and Cell Biology, Columbia University, College of Physicians and Surgeons, 701 W. 168th St., New York, New York 100324
Received 22 June 2005/ Accepted 11 November 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
During latency, viral DNA replication, late protein expression, and virion assembly do not occur. It has been reported that transcripts corresponding to the immediate-early and early open reading frames (ORFs) ORF4, -21, -29, -62, -63, and -66 are present in neurons harboring latent VZV (9-13, 15, 25, 36, 50). Proteins expressed by these ORFs are present in the cytoplasm of latently infected neurons (9, 12, 15, 36, 49, 50). In particular, Lungu et al. demonstrated that ORF29p, a single-stranded DNA binding protein that is predominantly nuclear during lytic infection, is restricted to the cytoplasm of latently infected neurons in explanted human dorsal root ganglia (49). Upon reactivation, ORF29p accumulates in the nuclei of neurons undergoing productive infection (49). The detection of ORF29p and the other latency-associated proteins (LAPs) in the cytoplasm suggests a tight correlation between their nuclear import/exclusion and the progression of VZV lytic infection.
Most stages of the VZV life cycle that occur in vivo can be recapitulated in vitro. Cell-free VZV infection is lytic in primary human fibroblasts and MeWo cells, a melanoma-derived cell line. During lytic infection of these cell lines, ORF29p localizes predominantly to subnuclear compartments (39). Conversely, infection of cultured guinea pig enteric ganglia (EG) with cell-free VZV results in a latent infection and cytoplasmic localization of ORF29p in neurons (9). Latent VZV in EG cultures may be reactivated by superinfection with adenoviruses expressing ORF61p or HSV-1 ICP0. In response to this superinfection, ORF29p accumulates in the nuclei of infected cells (J. Chen et al., submitted for publication).
During lytic infection, ORF29p is expressed from a bidirectional 221-bp intergenic regulatory element that is shared with its divergently oriented neighboring gene, ORF28, which encodes the viral DNA polymerase (51, 53, 66). Transcription from ORF29 produces a predominant polyadenylated RNA transcript of 4.2 kb and a minor transcript of 4.1 kb (53). Transcription from both genes is tightly coordinated and requires VZV immediate-early protein ORF62p for efficient expression (51-53, 66). During latent infection, only the 4.2-kb transcript of ORF29 is detected, while the ORF28 transcript is absent (10, 15, 16, 50). Therefore, the ORF28 and ORF29 genes may, depending on the replication state of the virus, be expressed either synchronously or independently of each other. This differential transcription of only ORF29 during latency suggests a role for neuron-specific transcription factors in its regulation.
VZV ORF29 encodes a nonstructural 130-kDa, single-stranded DNA binding protein that is an orthologue of herpes simplex virus type 1 (HSV-1) ICP8 (39, 60). ORF29p and ICP8 share 50% sequence homology at the amino acid level. However, most of this similarity resides in the DNA binding motifs, while other areas of the proteins are less conserved. In addition to its presumed role in DNA replication, transfection assays have revealed that ORF29p can also influence transcription from some ORF62p-responsive promoters (3). No protein interaction data have been reported for ORF29p. It is not phosphorylated during lytic infection, despite the existence of multiple putative phosphorylation sites (14, 60). ORF29p modifications during latent infection have yet to be investigated.
The molecular basis for ORF29p localization during VZV infection is unclear. ORF29p lacks a classical nuclear import sequence, export signal, or any homology to ICP8 targeting sequences (39, 61, 64). We have shown that ORF29p nuclear import occurs independent of the presence of other VZV-specified proteins and that its nuclear localization sequence (NLS) maps to amino acids 9 to 154. The ORF29p NLS interacts either directly or indirectly with karyopherin
and shuttles into the nucleus via a Ran-dependent pathway, which is well conserved in most human cells (35, 42, 62). This, along with the observation that ORF29p enters the nuclei of infected neurons during reactivation, suggests that the mechanism governing nuclear import of ORF29p is not the determinant of its cell-type-specific localization.
In this report, we analyze the cellular localization patterns of ORF29p during VZV infection and during autonomous expression in MeWo cells, U373MG cells, and cultured guinea pig enteric neurons. We also investigate the effect of ORF61p and HSV-1 ICP0 expression on ORF29p localization and provide plausible explanations for the cell-type-specific localization pattern of ORF29p. Our results demonstrate that differential compartmentalization of ORF29p is cell type specific but can be influenced by subsequent expression of ORF61p or ICP0. In these cases, ORF61p or ICP0 induces nuclear accumulation of ORF29p in cell lines where it is normally cytoplasmic. Inhibition of the 26S proteasome, but not heat shock treatment, also affects the cellular distribution of ORF29p similarly to ICP0 expression. Fluorescence microscopy and pulse-chase experiments demonstrate that redistribution of ORF29p to the nucleus correlates with protein stabilization. Induced nuclear accumulation of ORF29p is also dependent on the novel ORF29p NLS that we have previously defined (62). Although proteasome inhibition induces ORF29p nuclear accumulation, this is not sufficient to reactivate latent VZV in EG cultures. A better understanding of the expression and localization of ORF29p could help elucidate the mechanisms controlling VZV latency.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Guinea pig enteric ganglia were isolated and cultured as previously described (9). In brief, ganglia were seeded for culture in two-well chamber slides that were coated with 10 µg/ml each of poly-D-lysine and mouse laminin in DMEM-F12 (GIBCO-BRL) supplemented with 2% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml gentamicin, and 5.25 µg/ml amphotericin B (Fungizone). Mitotic inhibitors (10 µM 5-fluoro-2'-deoxyuridine, 10 µM uridine, and 1 µM cytosine ß-D-arabinofuranoside) (Sigma, St. Louis, MO) were also added. Prior to virus infection, the mitotic inhibitors were removed, and the cells were subsequently cultured in their absence.
Viruses. (i) VZV. Jones VZV, a wild-type clinical isolate, was propagated in MeWo cell monolayers by serial passage of infected cells onto uninfected cells as described previously (26). Cell-free Jones VZV was obtained by infecting MeWo cells in 175-cm2 tissue culture flasks until a cytopathic effect (CPE) was present. Infected cells were scraped in the maintenance medium and centrifuged at 577 x g for 10 min at 4oC in a Beckman CS-6KR refrigerated centrifuge. The cells were washed twice in cold phosphate-buffered saline (PBS) (1 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4) before being resuspended in 1ml of Hanks balanced salt solution per flask and sonicated twice for 30 s each. Cell debris was removed by centrifuging the lysed cells at 22 x g for 5 min at 4oC in a Tomy MX-160 high-speed refrigerated microcentrifuge. Cell-free virus stocks were stored in 0.5-ml aliquots at 80oC.
(ii) Adenoviruses.
Adenovirus vectors MLP-0, Ad-0/125, and Ad-0/88 express HSV-1 ICP0, ICP0 with an insertion at amino acid 124, and ICP0 with an insertion at amino acid 697, respectively, under control of the adenovirus major late promoter (MLP) (67, 68). Adenoviruses AdORF29 and AdORF29
NLS express ORF29p and ORF29p
NLS, respectively, under control of a mouse cytomegalovirus (mCMV) promoter and were constructed using a system (pDC516 and pBHGfrt
E1,3FLP) that relied on FLP-mediated frt site recombination (Microbix Biosystems, Inc., Toronto, Ontario, Canada) (54). An empty adenovirus vector, Ad.MmCMV, was constructed by cotransfection of pDC516 and pBHGfrt
E1,3FLP using the same system. Adenovirus AdORF61 expresses VZV ORF61p from the adenovirus MLP and was generated as described above. Viruses were plaque purified, stocks were produced, and titers were determined by fluorescent focus assays on 293A cells (58). All of the adenoviruses were propagated in 293A cells (24).
Proteasome inhibitor and cycloheximide treatment. Infected U373MG and MeWo cells were incubated in Eagle's minimal essential medium supplemented with 2% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and either dimethyl sulfoxide (DMSO) (Sigma), 20 µM MG132 (EMD Biosciences, La Jolla, CA) from a 10 mM stock in DMSO, 20 µM epoxomicin (EMD Biosciences) from a 1 mM stock in DMSO, or 50 µg/ml cycloheximide (Sigma) from a 10-mg/ml stock in water for the indicated period.
Plasmid construction. (i) ORF29 adenovirus vector construction.
p29-12 and pZErO29
NLS were constructed as previously described (62). ORF29 was released from p29-12 by digestion with EcoRI and PmlI and cloned into the EcoRI and SmaI sites of pDC516 (Microbix Biosystems) to generate pDC516-29, which was cotransfected with pBHGfrt
E1,3FLP (Microbix Biosystems) into 293A cells to generate AdORF29. An ORF29 gene containing a deletion in the NLS of nucleotides 459 to 821 was subcloned from pZErO29
NLS by using the same sites as for the full-length ORF29 fragment to generate pDC516ORF29
NLS, which was cotransfected with pBHGfrt
E1,3FLP into 293A cells to produce AdORF29
NLS.
(ii) ORF61 adenovirus vector construction.
The adenovirus MLP was released from pDS-2 (68) with SacII and HindIII and inserted into pBluescript II (Stratagene, La Jolla, CA) at the corresponding restriction enzyme sites to create pBS.MLP. pBS.MLP was digested with SacII, blunt ended with T4 DNA polymerase, and ligated with an EcoRI linker (New England Biolabs, Beverly, MA). VZV ORF61 was released from pGORF61 (33) by AccI digestion and subcloned into pDC511 at the AccI site. The adenovirus MLP was released from pBS.MLP by EcoRI and HindIII digestion and ligated into a pDC511 construct containing ORF61 that had been linearized using the same restriction enzymes. The resulting construct, pDC511.MLP.ORF61, was cotransfected with pBHGfrt
E1,3FLP into 293A cells to produce AdORF61. All vector inserts were verified by DNA sequencing.
Transfections.
The plasmids pDC516-29, pDC516ORF29
NLS, pDC511.MLP.ORF61, and pBHGfrt
E1,3FLP were cotransfected into 293A cells to make recombinant adenoviruses by using calcium phosphate precipitation as previously described (54).
Antibodies. Rabbit polyclonal antibodies against amino acids 1086 to 1201 of ORF29p and amino acids 765 to 868 of ORF62p were previously described (49). The mouse monoclonal antibody 1112 against HSV-1 ICP0 was purchased from the Goodwin Cancer Research Institute (Plantation, FL). A mouse monoclonal antibody to VZV gE was purchased from ViroStat (Portland, ME). Alexa Fluor 488-conjugated goat anti-mouse and Alexa Fluor 546 anti-rabbit antibodies were purchased from Molecular Probes (Carlsbad, CA). Goat anti-rabbit antibodies conjugated to horseradish peroxidase were purchased from KPL (Gaithersburg, MD).
Indirect immunofluorescence microscopy. Cells on glass coverslips were washed once with PBS, fixed for 25 min with 3.7% formaldehyde in PBS, washed two more times in PBS, and permeabilized with ice-cold acetone at 20oC for 10 min. Cells were washed twice more in PBS and blocked with 10% normal goat serum (Roche, Indianapolis, IN) in PBS plus 0.1% Tween 20 (Sigma, St. Louis, MO) (PBS-T) for 30 min. Cells were incubated with a 1:100 dilution of the appropriate primary antibody in 1% normal goat serum in PBS-T for 1 h and then washed three times for 5 min each in PBS-T. Cells were then incubated for 1 h with the appropriate Alexa Fluor-conjugated secondary antibody diluted 1:1,000 in 1% normal goat serum in PBS-T and washed once for 5 min with PBS-T, once for 10 min with PBS-T plus 0.5 µg/ml Hoechst 33258 (Sigma), and once again for 5 min in PBS-T. The coverslips were mounted with GEL/MOUNT (Biomeda, Foster City, CA).
All samples were visualized with a Zeiss Axiovert 200M inverted microscope, and images were acquired with a Zeiss Axiocam (Carl Zeiss Microimaging Inc., Thornwood, NY) by using Openlab 3.1 software (Improvision, Lexington, MA). Images were assembled with Adobe Photoshop (Adobe Systems Inc., San Jose, CA).
Pulse-chase metabolic labeling. Proteins were radiolabeled by first washing three times in PBS and starving the infected or control cell cultures of Met and Cys by incubating them with modified DMEM (GIBCO-BRL) for 30 min. Starvation medium was replaced with labeling medium supplemented with 1% dialyzed calf serum and 500 µCi/ml Tran35S-label (ICN, Irvine, CA). After a 1-h pulse, cells were washed three times with PBS and incubated for the indicated chase time in normal growth medium before harvesting.
Immunoprecipitation. Radioactively labeled cells were harvested, washed twice with PBS, resuspended in 500 µl radioimmunoprecipitation (RIPA) lysis buffer (10 mM Na2HPO4 [pH 7.2], 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) plus Complete protease inhibitor cocktail (Roche, Indianapolis, IN), and incubated on ice for 30 min. Cell extracts were clarified by centrifugation at 22,500 x g for 5 min at 4oC in a Tomy MX-160 high-speed refrigerated microcentrifuge. Proteins were immunoprecipitated overnight at 4oC with ORF29p antiserum conjugated to 50 µl of GammaBind Plus Sepharose beads (Amersham Biosciences). Beads were collected by centrifuging for 5 min at 400 x g at 4oC in a Tomy MX-160 high-speed refrigerated microcentrifuge and washed three times for 15 min each with RIPA buffer at 4oC. Immunoprecipitated proteins were released from beads by boiling in 50 µl PBS and 10 µl 6x SDS sample buffer (300 mM Tris-HCl [pH 6.8], 12% SDS, 0.6% bromophenol blue, 60% glycerol, 600 mM ß-mercaptoethanol) for 10 min and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Western blotting of cell lysates. Ten-centimeter dishes of infected MeWo and U373MG cells were harvested, washed twice with PBS, resuspended in 100 µl of RIPA lysis buffer plus Complete protease inhibitor cocktail (Roche), and incubated on ice for 30 min. Cell extracts were clarified by centrifugation at 22,500 x g for 5 min at 4oC in a Tomy MX-160 high-speed refrigerated microcentrifuge. Total protein concentration was measured using the Bio-Rad protein assay (Bio-Rad, Hercules, CA). Twenty microliters of 6x SDS sample buffer was added to the samples prior to boiling for 10 min and SDS-PAGE. The proteins were transferred to a nitrocellulose membrane (Schleicher & Schuell, Keene, NH) with a Bio-Rad Trans-Blot semidry apparatus before Western blotting. After blocking of the membrane in 4% nonfat milk in PBS-T, immobilized proteins were incubated with the ORF29p antibody at a 1:1,000 dilution in blocking solution for 1 h at room temperature. The membrane was washed three times in PBS-T, incubated with an anti-rabbit antibody conjugated to horseradish peroxidase at a 1:5,000 dilution in blocking solution for 1 h at room temperature, and washed again, and ORF29p was visualized by addition of the LumiGLO substrate (KPL) and exposure to X-ray film.
Northern blot analysis. Total RNA was isolated from infected MeWo and U373MG cells by using the TRIzol reagent (Invitrogen), Ten micrograms of total RNA was brought to 6 µl in diethyl pyrocarbonate-treated water and added to a solution of 1x MOPS (morpholinepropanesulfonic acid) (from a 10x stock; 0.2 M MOPS [pH 7.0], 20 mM sodium acetate, 10 mM EDTA [pH 8.0], 7.4% formaldehyde, 50% formamide, and 10 µg/ml of ethidium bromide). The samples were incubated at 85oC for 10 min, chilled on ice for 10 min, and combined with 1x formaldehyde gel loading buffer (from a 10x stock; 50% glycerol, 10 mM EDTA [pH 8.0], 0.25% [wt/vol] bromophenol blue, 0.25% [wt/vol] xylenecyanol FF). The RNA was subjected to gel electrophoresis on a 1% agarose gel containing 2.2 M formaldehyde and 1x MOPS in 1x MOPS electrophoresis buffer. A 0.24- to 9.5-kb RNA ladder (Invitrogen) and the NEB RNA ladder (New England Biolabs, Beverley, MA) were run alongside the samples as molecular size markers. After photography, the gel was rinsed briefly in diethyl pyrocarbonate-treated water and incubated in 0.05 M NaOH for 20 min to partially hydrolyze the RNA. The gel was then washed in 20x SSC (3.0 M NaCl, 0.3 M sodium citrate, pH 7) for 40 min before transfer to a nylon membrane (Schleicher & Schuell) by standard upward capillary transfer. When the transfer was complete, the nylon membrane was rinsed in 2x SSC, and the RNA was UV cross-linked using the UV Stratalinker 2400 (Stratagene). The membrane was dried and prehybridized in 6x SSC, 0.5% SDS, 0.1 mg/ml salmon testis DNA, and 5x Denhardt's solution (from a 50x stock; 10% [wt/vol] bovine serum albumin, 25 mM Ficoll, 1% [wt/vol] polyvinylpyrrolidone) at 67oC for 2 h.
To make an ORF29-specific DNA probe, the EcoRI NotI fragment containing ORF29 was excised from p29-12. Fifty nanograms of the released fragment or 50 ng of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mouse DECAprobe template (Ambion, Austin, TX) was added to a Boehringer Mannheim random-priming reaction mixture (Roche) in the presence of Redivue [
-32P]dCTP (Amersham Biosciences). The samples were incubated at 37oC for 30 min before the reaction was stopped by incubation with 25 mM EDTA for 10 min at 65oC. The unincorporated nucleotides were removed with the QIAquick nucleotide removal kit (Qiagen, Valencia, CA), and the probes were boiled, added to the prehybridization buffer, and incubated with the membrane overnight at 67oC. The membrane was washed once at room temperature with 1x SSC and 0.1% SDS for 10 min and then three times at 67oC with 0.5x SSC and 0.1% SDS for 15 min each before being exposed to X-ray film. Prehybridization, hybridization, and washes were performed in a Techne Hybridizer HB-1D (Burlington, NJ).
| RESULTS |
|---|
|
|
|---|
|
Localization of virus-specified proteins in cells infected with cell-free VZV. Infection of human fibroblasts and MeWo cells with cell-free VZV results in virus production, whereas infection of cultured EG results in latency (9, 62). ORF29p localization in these cases mimics what has been witnessed in vivo, in that ORF29p accumulates in the nucleus during lytic infection and in the cytoplasm during latency. Other hallmarks of lytic infection include nuclear distribution of the immediate-early gene product ORF62p and expression of the late protein gE (ORF68p). This is in contrast to the current model of latent infection, where the immediate-early protein ORF62p is excluded from the nucleus and late gene products are not detectable (9, 25, 40, 49).
MeWo cells, cultured EG, and U373MG cells were infected with cell-free VZV to determine whether both immediate-early and late proteins were expressed after infection of U373MG cells with cell-free VZV (Fig. 2). At 3 dpi, the cells were fixed and stained for ORF29p and gE (Fig. 2A), and ORF62p (Fig. 2B). Microscopic examination of VZV infected MeWo cells demonstrated cytopathic effects, nuclear accumulation of ORF29p, and expression of gE (Fig. 2A). In contrast, in enteric neurons infected with cell-free VZV, CPE was not detected, ORF29p and ORF62p were present only in the cytoplasm, and there was no detectable expression of gE (Fig. 2). This result mimics the localization pattern of ORF29p in human autopsy tissue (49).
|
ORF29p localization is influenced by expression of HSV-1 ICP0 or VZV ORF61p. To investigate further the mechanisms involved in differential compartmentalization of ORF29p, we asked what herpesvirus proteins influenced ORF29p localization and how. Therefore, cultured guinea pig enteric neurons were inoculated with cell-free VZV to establish a latent infection (Fig. 3) (9). At 3 dpi, these cultures were superinfected with MLP-0 (67, 68) and incubated for an additional 48 h. VZV in neuron cultures that were superinfected with an empty adenovirus vector (Ad.MmCMV) remained latent as evident by the cytoplasmic localization of ORF29p and ORF62p and the absence of the late gene product gE (Fig. 3A). ICP0 expression appeared to reactivate latent VZV in enteric neurons, as evidenced by nuclear accumulation of ORF29p and ORF62p and expression of the late gene product gE in these cells (Fig. 3B). These same results were observed with an adenovirus expressing the VZV-encoded ICP0 homologue ORF61p (AdORF61) (Fig. 3C).
|
|
In other studies we have established that the ORF29p NLS lies between amino acids 9 and 154 and that deletion of amino acids 153 to 272 abrogates ORF29p nuclear import (62). The requirement for this novel NLS for nuclear translocation of ORF29p in U373MG cells and EG was examined. EG, U373MG, and MeWo cells were infected with AdORF29
NLS, which expresses a protein that lacks an active NLS and therefore accumulates exclusively in the cytoplasm (Fig. 4E) (62). The effect of ICP0 expression on the localization of ORF29p
NLS was also investigated. Cultured EG and U373MG cells were infected as described above, and the intracellular distributions of ORF29p
NLS and ICP0 were analyzed by indirect IF. The NLS mutant protein remains cytoplasmic even after expression of ICP0 (Fig. 4C). Thus, the nuclear accumulation of ORF29p in cultured EG and U373MG cells induced by ICP0 expression utilizes the same NLS required for ORF29p nuclear import during lytic infection.
ICP0 exon 2 and 3 mutants are not able to affect ORF29p intracellular distribution. ICP0 is a multifunctional protein that affects the expression of many viral and cellular gene products (4, 17, 20, 21, 23, 27, 30, 34, 46, 48, 55-57, 67). To determine more precisely the effect of ICP0 expression on ORF29p localization, the regions of ICP0 involved in ORF29p redistribution were investigated using ICP0 mutant adenoviruses, Ad-0/125 and Ad-0/88, previously characterized in our laboratory (67). Ad-0/125 and Ad-0/88 are linker insertion mutants that have five amino acid insertions at positions 124 and 697 of the ICP0 protein, respectively. The insertion at amino acid 124 falls within the zinc finger domain in exon 2 and eliminates ICP0 transactivation and reactivation activity. The insertion at position 697 lies in exon 3 and had no effect on ICP0's ability to activate transcription or reactivate latent HSV (8, 67). U373MG cells were first infected with AdORF29, and 3 days later the cells were superinfected with Ad-0/125 and Ad-0/88 and incubated for an additional 48 h. The cells were fixed, and the distributions of ORF29p and ICP0 were determined by indirect IF. The ICP0 proteins expressed by Ad-0/125 and Ad-0/88 localized to the nuclei of infected U373MG cells, but they were unable to target ORF29p to the nucleus in cells coexpressing both proteins (Fig. 5A). This differs from the case for wild-type ICP0, which when expressed in cells containing ORF29p results in nuclear accumulation of the latter. Superinfection with Ad-0/125 and Ad-0/88 had no effect on ORF29p localization in MeWo cells (data not shown).
|
Effect of proteasome inhibitors on ORF29p localization. Given the requirement for the exon 2 and 3 domains of ICP0 to localize ORF29p to the nucleus in U373MG cells, we asked whether proteasome activity is involved in nuclear translocation. Cultured EG, U373MG, and MeWo cells infected with AdORF29 were treated at 3 dpi with 20 µM MG132 or DMSO for 6 h before analysis of the intracellular distribution of this protein by indirect IF. MG132 is a peptide aldehyde that potently, but reversibly, inhibits the chymotrypsin-like activity of the 26S proteasome (41, 44). Following inhibition of proteasome activity, ORF29p accumulates in the nuclei of cultured enteric neurons and U373MG cells, while addition of DMSO has no effect on ORF29p localization in either cell type (Fig. 6). MG132 treatment had no effect on ORF29p localization in the nuclei of MeWo cells (Fig. 6C).
|
The cytoplasmic localization of ORF29p
NLS is unaffected in U373MG cells treated with epoxomicin (Fig. 6D). We surmise from these results that proteasome inhibitor-induced ORF29p nuclear accumulation in U373MG cells uses the NLS that we previously defined for nuclear import in all cell types examined (62).
Blocking of protein degradation with proteasome inhibitors leads to a buildup of ubiquitinated, misfolded, and damaged proteins. This in turn triggers the heat shock response, which alters the cell environment and thereby makes interpretation of proteasome inhibition data difficult (41, 44). Therefore, we next asked if heat shock was able to alter the localization of ORF29p. U373MG and MeWo cells were infected with AdORF29 at an MOI of 50. At 3 dpi, infected cells were incubated at 42oC for 30 min and allowed to recover for 1 h at 37oC prior to fixing and staining for ORF29p localization. Heat shock treatment did not alter ORF29p localization in either cell line, indicating that the heat shock response is not sufficient to relocate ORF29p into the nuclei of U373MG cells (data not shown).
ORF29p is less stable in the cytoplasm than in the nuclei of U373MG and MeWo cells. The alteration of ORF29p subcellular localization in cultured EG and U373MG cells in response to proteasome inhibition raised the question of whether the protein's stability contributed to its cellular compartmentalization. To investigate this, U373MG and MeWo cells infected with AdORF29 were treated at 3 dpi with either DMSO or 50 µg/ml of cycloheximide for 6 h to inhibit protein translation. Cells were fixed, and ORF29p localization was examined by IF analysis (Fig. 7). Following cycloheximide treatment, the intensity of the cytoplasmic signal from ORF29p diminished in U373MG cells but not in MeWo cells, where the strong signal in the nucleus remained.
|
Two biochemical experiments were done to correlate the abundance and stability of ORF29p in the different cell types with its localization pattern. First, MeWo and U373MG cells were infected with AdORF29 at an MOI of 50, and at 3 dpi the infected cultures were either mock treated, treated with MG132, or treated with cycloheximide for 6 h. Cell lysates were prepared and analyzed by Western blotting for ORF29p (Fig. 8). The total protein loaded into each well was normalized by correcting for the abundance of a nonspecific protein band that cross-reacts with the antibody to ORF29p. The change in abundance of ORF29p in MeWo and U373MG cells was calculated as the percentage of protein present in the mock-treated samples (Fig. 8). Analysis of the ORF29p level following these treatments reveals that it more than doubled after MG132 treatment of U373MG cells and decreased by 25% when protein synthesis was inhibited. ORF29p levels in MeWo cells increased slightly after MG132 and cycloheximide treatment, but not to the same extent as seen in U373MG cells. Thus, ORF29p is less stable in U373MG cells than in MeWo cells, and this stability is affected by inhibition of the proteasome and translation. The increased stability of ORF29p in U373MG cells following MG132 treatment also correlates with its appearance in the nucleus.
|
|
|
NLS-infected MeWo and U373MG cells to determine whether nuclear import was necessary for the survival of ORF29p in MeWo cells. Figure 10A demonstrates that ORF29p
NLS was almost completely degraded after a 6-h chase in MeWo cells, and treatment with MG132 was able to stabilize only 33% of the protein. ORF29p
NLS was more stable than the wild type in DMSO-treated U373MG cells, but only 32% of the protein remained after a 6-h chase (Fig. 10B). Like its wild-type protein counterpart, ORF29p
NLS was stabilized when proteasome activity was inhibited in U373MG cells. The fact that ORF29p
NLS is unstable in MeWo cells suggests that ORF29p needs to reach the nucleus to survive. Analysis of ORF29 mRNA from AdORF29-infected cells. The pulse-chase experiments demonstrate that ORF29p is stabilized in U373MG cells after treatment with MG132. These experiments, however, do not exclude the possibility that inhibition of the proteasome up-regulated transcription factors, resulting in increased accumulation of the RNA encoding ORF29p. Northern blot analysis of ORF29 mRNA from AdORF29 or VZV infection of MeWo and U373MG cells was done to investigate this point. ORF29 mRNA from both adenovirus- and VZV-infected cells resolved as a single species of 4.2 kb under the conditions of our analysis (data not shown). In a previous report, Meier et al. stated that during lytic infection of fibroblasts, ORF29 is transcribed as two species that migrate at 4.1 and 4.2 kb (50). In that study, transcription of ORF29 was shown to initiate at two sites. An mCMV promoter drives the adenovirus expression cassette used in the current study, and therefore only a single RNA species is predicted. Interestingly, when MeWo and U373MG cells infected with AdORF29 were treated with MG132 for 6 h, the ORF29 RNA levels increased in both cell lines while the level of GAPDH RNA remained constant. The percent increase in ORF29 RNA levels between treated and untreated samples was similar in MeWo and U373MG cultures. This result does not account for the twofold increase in protein levels observed following MG132 treatment of U373MG but not MeWo cells (Fig. 8). Thus, the increase in ORF29 RNA levels is not sufficient to account for the accumulation of protein in U373MG cells.
MG132 reversal induces ORF29p degradation and accumulation of de novo protein in the cytoplasm. To determine whether nuclear translocation protected ORF29p from proteasome degradation, we took advantage of the fact that the action of MG132 is reversible (41, 44). At 3 dpi with AdORF29, U373MG cells were treated for 6 h with MG132. The cells were then washed and incubated for an additional 6 h in normal growth medium containing either DMSO or 50 µg/ml of cycloheximide (Fig. 11). Immunofluorescence microscopy demonstrated that ORF29p accumulated in the cytoplasm of U373MG cells when the inhibitory activity of MG132 was reversed. If protein synthesis was inhibited during and after reversal, ORF29p was cytoplasmic but barely detectable. Thus, the accumulation of ORF29p in the cytoplasm results from de novo synthesis, and nuclear ORF29p that amasses during treatment with MG132 is subsequently either degraded in situ or exported to the cytoplasm and destroyed. There are no reports on whether ORF29p shuttles, although leptomycin B has no effect on ORF29p localization in U373MG cells (data not shown). However, this observation only rules out the involvement of a CRM1-dependent export pathway (29, 43).
|
B to the nuclei of infected cells, which then up-regulates NF-
B-responsive genes that may aid in viral replication (17). To determine whether the subcellular location of the latency-associated proteins was altered by inhibition of the proteasome and to determine if the virus was reactivated in response to the drug, latently infected enteric neurons were either mock treated, superinfected with MLP-0, or treated with 20 µM MG132. The cells were fixed and scored for the expression of ORF29p, ORF62p, and gE by IF analysis (Fig. 3 and 12A). As expected, VZV infection remained latent in mock-treated cells, as demonstrated by the presence of ORF29p and ORF62p in the cytoplasm and the absence of gE (Fig. 12). Superinfection of cultures with MLP-0 reactivated latent VZV in cultured enteric neurons as judged by the presence of ORF29p and ORF62p in the nucleus and expression of gE (Fig. 3). MG132 treatment of latently infected EG resulted in nuclear accumulation of ORF29p without gE expression (Fig. 12A). The absence of gE and CPE indicates that while inhibition of the proteasome results in nuclear import of ORF29, it is not sufficient to reactivate VZV. Moreover, treatment with MG132 did not affect ORF62p localization in latently infected neurons (Fig. 12A). Thus, nuclear localization of ORF29p can occur independent of translocation of the other LAPs.
|
| DISCUSSION |
|---|
|
|
|---|
Whether the expression and cytoplasmic localization of the VZV LAPs during latent infection is a consequence of related events or independent activities has not been established. We have previously shown that nuclear import of ORF29p occurs independent of the presence of other VZV-specified proteins via the classical nuclear import pathway, which is well conserved in most human cells (62). This was not surprising, as ORF29p enters the nuclei of infected neurons during reactivation. Nevertheless, the question of how ORF29p is excluded from the nucleus during latency remains.
In this report we demonstrate that differential compartmentalization of ORF29p is cell type dependent but can be altered in response to the expression of other virus proteins. Autonomous expression of ORF29p in U373MG cells and cultured guinea pig EG results in accumulation of this protein in the cytoplasm. This observation implies that nuclear exclusion during latency occurs independently of the distribution of other virus proteins. Because U373MG cells cannot support latent infection, we infer that the distribution profile of ORF29p is susceptible to change in response to expression of other VZV gene products. Specifically, we demonstrate that subsequent expression of either ORF61p or HSV-1 ICP0 results in the accumulation of ORF29p in the nuclei of cells where it normally remains cytoplasmic when autonomously expressed. This redistribution requires the protein's NLS, which is consistent with the hypothesis that the mechanism of ORF29p nuclear import is conserved among all human cell lines tested. The expression of ORF61p or ICP0 must, therefore, alter the environment of the host cell to permit redistribution to the nucleus. It is possible that during VZV latency a similar alteration in the pathogen-host interface induces reactivation.
The sensitivity of ORF29p subcellular localization to proteasome inhibitors revealed a role for the proteasome degradation system in this process. Proteasomes are large, multisubunit complexes, present in the nucleus and cytosol, that selectively degrade intracellular proteins. The pathway plays a major role in the degradation of many proteins involved in the cell cycle, proliferation, and apoptosis. The proteasome machinery also serves to remove abnormal proteins that might otherwise disrupt normal cellular homeostasis. A protein destined for degradation is generally marked by the covalent attachment of multiple ubiquitin moieties that escort it to the 26S proteasome for rapid hydrolysis. Ubiquitin is ligated to target proteins by a multienzymatic system consisting of ubiquitin-activating (E1), ubiquitin-conjugating (E2), and ubiquitin-ligating (E3) enzymes (32). An increase in the half-life of ORF29p in U373MG cells correlates with the nuclear accumulation of this protein following treatment with MG132, further implicating this pathway in the fate of ORF29p.
The short half-life of ORF29p in U373MG cells suggests that it is being directly targeted for degradation by the 26S proteasome. Additionally, at the 6-h time point during pulse-chase analysis in MeWo cells, antigenically related species that are both larger and smaller than ORF29p are detected, and they are less abundant in the samples treated with MG132 (Fig. 9A). ORF29p-related species with the same molecular weights are detected at all chase time points in U373MG cells and are also more abundant at later times in untreated cells (Fig. 9B). These larger and smaller ORF29p-related species that are also detected by Western analysis might represent modified and degraded peptides, respectively. The existence of similar species in both cell types suggests that the modification and breakdown of ORF29p occur ubiquitously but to various degrees. During productive VZV infection, ORF29p is detected at low levels in the cytoplasm of all cells (39, 49). Curiously, despite its presence in the cytoplasm, ORF29p is not packaged in the VZ virion, indicating that it does not gain access to the assembly machinery in the trans-Golgi network (38, 60, 69). We speculate that the susceptibility of cytoplasmic ORF29p to degradation precludes it from being packaged.
During HSV-1 infection, ICP0 hijacks the ubiquitin-mediated proteasome degradation pathway components to create a cellular environment more conducive for productive infection. The interaction of ICP0 with the proteasome is normally dynamic, but in cells where the activity of the proteasome is inhibited, this association is stabilized (17, 22, 65). Our studies show that expression of ICP0 or ORF61p or inhibition of the proteasome results in nuclear localization of ORF29p. Mutations in regions of ICP0 involved in its association with components of the proteasome pathway abrogate its effect on ORF29p. We propose that this link between physical association and function results in sequestration by ICP0 of the proteasome machinery, with the result being stabilization of ORF29p. While there is no evidence for ORF61p involvement in the proteasome pathway, the most highly conserved domain between it and ICP0 is the ring finger encoded by exon 2. This domain has been demonstrated to possess E3 ubiquitin ligase activity and to bind the cdc32 E2 ubiquitin-conjugating enzyme (5, 17, 28, 65).
The enhanced stability of ORF29p correlates with its nuclear accumulation. Reversal of the action of MG132 demonstrates that ORF29p nuclear translocation does not guarantee its survival, as the protein's distribution and stability are reset when inhibition of proteasome activity is reversed. The stabilization of ORF29p, therefore, leads to its nuclear accumulation. The disappearance of ORF29p from the nucleus upon removal of the drug also suggests that ORF29p is either exported from or degraded in the nuclei of U373MG cells.
It was intriguing that although MG132 treatment induced ORF29p nuclear accumulation, this was not sufficient to reactivate latent VZV in cultured enteric neurons. Even after removal of MG132, virus remains latent and ORF29p reappears in the cytoplasm. Similar drug reversal experiments with U373MG cells in the presence of cycloheximide demonstrate that following reversal of inhibition of the proteasome, ORF29p is either destroyed in situ or exported for degradation. The regulation of ORF29p by the host cell during latency may therefore involve both nuclear exclusion and protein stability. MG132 treatment of latently infected neurons had no effect on ORF62p distribution, which suggests that compartmentalization of these two proteins during latency occurs via independent mechanisms. It is possible that a threshold for nuclear transport exists, as stabilization of the protein also allows for some nuclear accumulation.
The VZV infectious cycle is cell type specific in that invasion of the epidermis and dermis results in a lytic infection, while infection of the sensory ganglia leads to latency. ORF29p subcellular distribution and stability are also cell type dependent according to the state of VZV infection. Therefore, host factors must provide a cellular environment that is permissive to VZV latent infection. Our studies implicate the proteasome degradation pathway in control of the subcellular distribution of ORF29p. The involvement of the proteasome in cell-type-specific regulation of herpesvirus proteins has been documented for HSV-1 UL9, the virus DNA replication initiator, which is specifically targeted to the 26S proteasome in neurons (18, 19, 45). We postulate that fibroblasts may encode a mechanism that protects ORF29p from destruction and allows for nuclear import. Alternatively, U373MG cells and enteric neurons actively target ORF29p to the proteasome and thus abrogate nuclear translocation of this protein during AdORF29 infection.
In the context of VZV infection, it is conceivable that other virus-specified proteins also contribute to the mechanisms affecting ORF29p expression and subcellular distribution. The elucidation of the interplay between cellular pathways and virus proteins in the regulation of the differential compartmentalization of ORF29p and the other LAPs may expand our understanding of VZV latency and reactivation.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|